Fourth Quarter 2018 Summary
– Oncology gross orders grew 13% in dollars, or 14% in constant currency
– 84 Halcyon orders in the quarter
– Total company revenues of $802 million grew 11%, or 12% in constant currency
– GAAP operating earnings grew 29% at 16.8% of revenues; Non-GAAP operating earnings grew 14% at 17.8% of revenues
– GAAP net earnings per diluted share from continuing operations of $1.26; Non-GAAP net earnings per diluted share from continuing operations of $1.16
Fiscal Year 2018 Summary
– Oncology gross orders grew 9%, or 8% in constant currency
– Added 224 linear accelerators to the installed base which is now greater than 8,000 units
– Total company revenues of $2.9 billion grew 11%, or 10% in constant currency
– GAAP operating earnings grew 47% at 15.1% of revenues; Non-GAAP operating earnings grew 31% at 17.7% of revenues
– GAAP net earnings per diluted share from continuing operations of $1.62; Non-GAAP net earnings per diluted share from continuing operations of $4.42